Joaquı́n Arribas

Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer

Maurizio Scaltriti, Federico Rojo, Alberto Ocaña et al. · JNCI Journal of the National Cancer Institute · 2007 · 881 citations · Full text

Medicine, Cancer Biology, Oncology +17

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

Violeta Serra, Ben Markman, Maurizio Scaltriti et al. · Cancer Research · 2008 · 796 citations · Full text

Medicine, Oncology, Pharmacology +16

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Jordi Codony‐Servat, Joan Albanell, Federico Rojo et al. · PubMed · 2001 · 775 citations

Medicine, Molecular Biology, Oncology +16

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Violeta Serra, Maurizio Scaltriti, Ludmila Prudkin et al. · Oncogene · 2011 · 534 citations · Full text

Medicine, Cancer Biology, Pharmacology +17

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

Maurizio Scaltriti, Chandra Verma, Marta Guzmán et al. · Oncogene · 2008 · 444 citations

Medicine, Cancer Biology, Oncology +15